Profile data is unavailable for this security.
About the company
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.
- Revenue in USD (TTM)651.97m
- Net income in USD59.71m
- Incorporated2005
- Employees652.00
- LocationSupernus Pharmaceuticals Inc9715 Key West AvenueROCKVILLE 20850United StatesUSA
- Phone+1 (301) 838-2500
- Fax+1 (302) 636-5454
- Websitehttps://www.supernus.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANI Pharmaceuticals Inc | 538.95m | 22.95m | 1.29bn | 642.00 | 51.67 | 2.84 | 15.17 | 2.40 | 1.19 | 1.19 | 27.93 | 22.81 | 0.6055 | 1.81 | 3.18 | 839,490.60 | 3.04 | -2.83 | 3.56 | -3.35 | 61.34 | 60.18 | 5.01 | -6.15 | 3.07 | 3.10 | 0.3725 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Tilray Brands Inc | 812.04m | -212.62m | 1.35bn | 2.65k | -- | 0.375 | -- | 1.66 | -0.2746 | -0.2746 | 1.03 | 3.97 | 0.1875 | 2.31 | 8.73 | 306,429.10 | -4.64 | -- | -5.15 | -- | 29.42 | -- | -24.78 | -- | 1.57 | -1.16 | 0.0953 | -- | 25.80 | -- | 83.14 | -- | -- | -- |
| Avadel Pharmaceuticals PLC (ADR) | 95.15m | -106.22m | 1.53bn | 154.00 | -- | 21.82 | -- | 16.13 | -1.17 | -1.17 | 1.04 | 0.7306 | 0.5308 | 0.6941 | 5.41 | 617,850.60 | -59.26 | -40.21 | -80.97 | -47.99 | 94.62 | -- | -111.64 | -374.75 | 2.52 | -10.25 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
| Ocular Therapeutix Inc | 61.10m | -138.36m | 1.73bn | 267.00 | -- | 4.57 | -- | 28.33 | -1.09 | -1.09 | 0.5249 | 2.43 | 0.191 | 2.36 | 2.12 | 228,827.70 | -43.26 | -46.70 | -47.93 | -54.18 | 90.84 | 89.36 | -226.46 | -228.65 | 16.55 | -11.30 | 0.1509 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| Immunocore Holdings PLC - ADR | 281.45m | -53.44m | 1.74bn | 497.00 | -- | 4.83 | -- | 6.17 | -1.07 | -1.07 | 5.55 | 7.18 | 0.3556 | 0.5679 | 5.56 | 566,303.60 | -6.75 | -27.55 | -8.35 | -36.82 | 99.41 | -- | -18.99 | -97.12 | 5.15 | -- | 0.5495 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Harrow Inc | 154.15m | -33.58m | 1.86bn | 315.00 | -- | 31.83 | -- | 12.09 | -0.9508 | -0.9508 | 4.38 | 1.65 | 0.581 | 4.95 | 4.39 | 489,352.40 | -12.66 | -10.86 | -14.77 | -12.71 | 71.16 | 70.75 | -21.78 | -15.35 | 2.43 | -0.3518 | 0.7608 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Tarsus Pharmaceuticals Inc | 83.37m | -150.07m | 1.88bn | 244.00 | -- | 7.45 | -- | 22.55 | -4.43 | -4.43 | 2.43 | 6.63 | 0.2947 | -- | 5.36 | 341,696.70 | -53.05 | -31.56 | -60.10 | -33.82 | 92.50 | -- | -180.00 | -242.59 | 6.99 | -- | 0.221 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
| Endo Inc | -100.00bn | -100.00bn | 1.93bn | 3.00k | -- | 1.05 | -- | -- | -- | -- | -- | 23.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.52 | -- | 0.5697 | -- | -13.25 | -- | 15.87 | -- | -- | -- |
| Supernus Pharmaceuticals Inc | 651.97m | 59.71m | 2.02bn | 652.00 | 34.27 | 2.01 | 14.14 | 3.10 | 1.07 | 1.07 | 11.71 | 18.24 | 0.4962 | 0.9689 | 4.54 | 999,957.10 | 4.54 | 4.95 | 5.83 | 6.41 | 89.04 | 88.61 | 9.16 | 12.84 | 1.98 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
| Harmony Biosciences Holdings Inc | 681.88m | 122.63m | 2.06bn | 246.00 | 17.08 | 3.45 | 14.01 | 3.02 | 2.11 | 2.11 | 11.75 | 10.46 | 0.7994 | 24.26 | 9.17 | 2,771,866.00 | 14.38 | 7.46 | 17.12 | 9.08 | 78.65 | 80.58 | 17.98 | 10.46 | 3.20 | -- | 0.2345 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
| Ligand Pharmaceuticals Inc | 133.48m | 42.14m | 2.22bn | 58.00 | 54.50 | 2.83 | 28.66 | 16.60 | 2.22 | 2.22 | 7.33 | 42.82 | 0.1643 | 0.4789 | 4.08 | 2,301,345.00 | 5.19 | 12.32 | 5.35 | 12.99 | 91.82 | 81.65 | 31.57 | 80.32 | 15.81 | -- | 0.00002 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
| Amphastar Pharmaceuticals Inc | 712.89m | 166.52m | 2.34bn | 1.76k | 15.39 | 3.32 | 10.64 | 3.28 | 3.14 | 3.14 | 13.45 | 14.57 | 0.4968 | 2.85 | 6.04 | 404,821.70 | 11.71 | 9.42 | 13.54 | 11.56 | 54.68 | 47.83 | 23.56 | 15.23 | 2.63 | 7.42 | 0.4515 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Vericel Corp | 214.52m | 789.00k | 2.65bn | 314.00 | 2,855.63 | 10.86 | 445.88 | 12.34 | 0.0189 | 0.0189 | 4.46 | 4.97 | 0.624 | 4.41 | 4.97 | 683,184.70 | 0.2295 | -3.07 | 0.2595 | -3.50 | 70.42 | 67.87 | 0.3678 | -4.49 | 4.16 | -- | 0.0008 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| Twist Bioscience Corp | 295.21m | -220.31m | 2.66bn | 919.00 | -- | 5.41 | -- | 9.01 | -3.81 | -3.81 | 5.12 | 8.39 | 0.4076 | 5.42 | 8.56 | 321,229.60 | -30.42 | -30.50 | -33.85 | -33.84 | 40.53 | 36.02 | -74.63 | -113.33 | 4.52 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
| Amneal Pharmaceuticals Inc | 2.60bn | -174.62m | 2.70bn | 7.70k | -- | -- | 29.36 | 1.04 | -0.6224 | -0.6224 | 10.09 | -0.1857 | 0.7206 | 3.00 | 3.60 | 337,401.60 | -3.69 | -4.80 | -4.93 | -5.93 | 35.04 | 34.76 | -5.13 | -9.00 | 0.8165 | 1.24 | 1.00 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
Data as of Nov 08 2024. Currency figures normalised to Supernus Pharmaceuticals Inc's reporting currency: US Dollar USD
62.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Jun 2024 | 8.57m | 15.55% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 6.04m | 10.95% |
| Armistice Capital LLCas of 30 Jun 2024 | 5.27m | 9.57% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 2.76m | 5.01% |
| Macquarie Investment Management Business Trustas of 30 Sep 2024 | 2.63m | 4.78% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 2.16m | 3.93% |
| Polar Capital LLPas of 30 Jun 2024 | 1.94m | 3.52% |
| Stephens Investment Management Group LLCas of 30 Sep 2024 | 1.93m | 3.51% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 1.69m | 3.06% |
| Loomis, Sayles & Co. LPas of 30 Jun 2024 | 1.56m | 2.82% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
